Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
Miricorilant
Nonalcoholic Steatohepatitis (Nash), Metabolic Dysfunction-Associated Steatohepatitis (Mash), Metabolic Dysfunction-Associated Steatotic Liver Disease (Masld), Non-Alcoholic Fatty Liver Disease (Nafld)
Phase I
Recruiting
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Apr 21, 2025
Dazucorilant
Hepatic Impairment
Phase I
Completed
Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant
Apr 08, 2025
―
Nab-Paclitaxel 80 Mg/M^2, Relacorilant 150 Mg Once Daily (Qd), Bevacizumab 10 Mg/Kg
Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Neoplasms
Phase II
Recruiting
Relacorilant in Combination With Nab-paclitaxel and Bevacizumab in Advanced, Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Apr 01, 2025
―
Itraconazole, Dazucorilant
Healthy Adults
Phase I
Completed
Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants
Jul 03, 2024
―
Miricorilant (Cohort A), Miricorilant (Cohort B)
Nonalcoholic Steatohepatitis, Metabolic Dysfunction-associated Steatohepatitis
Phase II
Active Not Recruiting
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
Oct 23, 2023
―
Cort125134 150 Mg, Cort125134 250 Mg, Cort125134 Dose To Be Determined
Healthy
Phase I
Completed
A Study to Evaluate the Pharmacokinetics of the Current Capsule Formulation of CORT125134 in Healthy Subjects
Oct 17, 2023
―
Cort125134
Healthy
Phase I
Completed
A Study to Evaluate the Pharmacokinetics of the CORT125134 Phase 2 Formulation in Healthy Male Subjects
Oct 17, 2023
―
Relacorilant
Hepatic Impairment
Phase I
Completed
A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
Oct 17, 2023
―
Relacorilant Under Fasted Conditions, Relacorilant After A High-Fat Meal, Relacorilant After A Low-Fat Meal
Healthy
Phase I
Completed
A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
Oct 17, 2023
―
Mifepristone 300 Mg [Korlym]
Hypercortisolism, Diabetes Mellitus, Type 2
Phase IV
Completed
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
Mar 06, 2023
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Corcept Therapeutics Inc. (CORT) have in its pipeline
CORT is currently developing the following drugs: Miricorilant, Dazucorilant, Nab-Paclitaxel 80 Mg/M^2, Relacorilant 150 Mg Once Daily (Qd), Bevacizumab 10 Mg/Kg. These drug candidates are in various stages of clinical development as the company works toward FDA approval.